Literature DB >> 20953748

Identification of peptide mimotopes of gp96 using single-chain antibody library.

Arulkumaran Shanmugam1, Robert Suriano, Neha Goswami, Devyani Chaudhuri, Badithe T Ashok, Shilpi Rajoria, Andrea L George, Abraham Mittelman, Raj K Tiwari.   

Abstract

Heat shock proteins such as gp96 are immunogenic and are widely used as vaccines in immunotherapy of cancers. The present study focuses on the use of peptide mimotopes as immunotherapeutic vaccines for prostate cancer. To this end, we developed a 15-mer gp96 peptide mimotope specifically reactive to MAT-LyLu gp96-peptide complex using combinatorial single-chain antibody and peptide phage display library. The immunogenicity of the synthesized gp96 mimotope was analyzed initially in normal BALB/c mice in combination with various adjuvants such as complete Freund's adjuvant (CFA), aluminum salts (ALUM), granulocyte-macrophage colony-stimulating factor (GM-CSF), and liposome, of which CFA served as a positive control. The antibody response was determined and found that the gp96 mimotope with ALUM showed a significant increase in antibody titer, followed by GM-CSF and liposomes. Further, the T cell (CD4(+) and CD8(+)) populations from splenocytes, as well as IgG isotypes, interleukin-4, and interleukin-5 of gp96 mimotope with ALUM-immunized animals, were analyzed. The results suggest that the gp96 mimotope may elicit a potent and effective antitumor antibody response. Further, the study identifies ALUM and GM-CSF as adjuvant options to drive an appropriate protective immune response as these adjuvants have prior use in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20953748      PMCID: PMC3059791          DOI: 10.1007/s12192-010-0234-6

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  41 in total

1.  Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.

Authors:  Amy D H Doody; Joseph T Kovalchin; Marianne A Mihalyo; Adam T Hagymasi; Charles G Drake; Adam J Adler
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.

Authors:  Devi SenGupta; Philip J Norris; Todd J Suscovich; Mina Hassan-Zahraee; Howell F Moffett; Alicja Trocha; Rika Draenert; Philip J R Goulder; Robert J Binder; Daniel L Levey; Bruce D Walker; Pramod K Srivastava; Christian Brander
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

Review 3.  Heat shock protein-based cancer vaccines.

Authors:  Yasuhiro Oki; Anas Younes
Journal:  Expert Rev Vaccines       Date:  2004-08       Impact factor: 5.217

Review 4.  Cytokine function of heat shock proteins.

Authors:  Min-Fu Tsan; Baochong Gao
Journal:  Am J Physiol Cell Physiol       Date:  2004-04       Impact factor: 4.249

5.  Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

Authors:  Vincenzo Mazzaferro; Jorgelina Coppa; Matteo G Carrabba; Licia Rivoltini; Marcello Schiavo; Enrico Regalia; Luigi Mariani; Tiziana Camerini; Alfonso Marchianò; Salvatore Andreola; Roberto Camerini; Marco Corsi; Jonathan J Lewis; Pramod K Srivastava; Giorgio Parmiani
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

6.  The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells.

Authors:  Robert Gastpar; Catharina Gross; Lydia Rossbacher; Joachim Ellwart; Julia Riegger; Gabriele Multhoff
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

7.  Tumor rejection antigens of chemically induced sarcomas of inbred mice.

Authors:  P K Srivastava; A B DeLeo; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

8.  Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo.

Authors:  H Udono; D L Levey; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors.

Authors:  P K Srivastava; Y T Chen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  Antibody fragments from a 'single pot' phage display library as immunochemical reagents.

Authors:  A Nissim; H R Hoogenboom; I M Tomlinson; G Flynn; C Midgley; D Lane; G Winter
Journal:  EMBO J       Date:  1994-02-01       Impact factor: 11.598

View more
  1 in total

1.  Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants.

Authors:  Arulkumaran Shanmugam; Shilpi Rajoria; Andrea L George; Abraham Mittelman; Robert Suriano; Raj K Tiwari
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.